Markus Warmuth
Impact in
- Hematology top 0.5%
- Chronic Myeloid Leukemia Treatments
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Papers in
- Hematology 22
- Chronic Myeloid Leukemia Treatments 18
-
- RNA Research and Splicing 9
- Protein Kinase Regulation and GTPase Signaling 8
- Hedgehog Signaling Pathway Studies 7
- Co-authors
- Michael J. Hallek (11 shared papers)Doriano Fabbro (4 shared papers)Katja Zirlik (5 shared papers)Christine Dierks (5 shared papers)Hendrik Veelken (5 shared papers)Gang Xia (4 shared papers)Susanne Danhauser-riedl (4 shared papers)Paul William Manley (4 shared papers)
- Journals
- Blood (7 papers)Nature (6 papers)Cancer Research (4 papers)Nature Medicine (3 papers)Nature Communications (3 papers)
- Partner nations
- United StatesGermanySwitzerland
In The Last Decade
Markus Warmuth
68 papers receiving 14.7k citations
Markus Warmuth's Hit Papers
Peers
Comparison fields: 5 of 128
- Hematology 2k
- Cancer Research 1.8k
- Molecular Biology 6.4k
- Computational Theory and Mathematics 1.6k
- Oncology 2.1k
Countries citing papers authored by Markus Warmuth
This map shows the geographic impact of Markus Warmuth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Warmuth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Warmuth more than expected).
Fields of papers citing papers by Markus Warmuth
This network shows the impact of papers produced by Markus Warmuth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Warmuth. The network helps show where Markus Warmuth may publish in the future.
Co-authors
The 25 scholars most cited alongside Markus Warmuth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Hit paper breakdown → | 2012 | 6239 |
| 2 | Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases Hit paper breakdown → | 2016 | 737 |
| 3 | Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors Hit paper breakdown → | 2010 | 513 |
| 4 | 2010 | 502 | |
| 5 | The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 Hit paper breakdown → | 2017 | 492 |
| 6 | 2008 | 444 | |
| 7 | 2018 | 416 | |
| 8 | Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials Hit paper breakdown → | 2013 | 371 |
| 9 | 2015 | 367 | |
| 10 | Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 Hit paper breakdown → | 2018 | 365 |
| 11 | 2004 | 343 | |
| 12 | 2006 | 327 | |
| 13 | 2010 | 291 | |
| 14 | 2007 | 277 | |
| 15 | 2011 | 257 | |
| 16 | 2010 | 210 | |
| 17 | 2006 | 189 | |
| 18 | 2010 | 162 | |
| 19 | Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. | 1996 | 161 |
| 20 | 2006 | 153 |
About Markus Warmuth
Markus Warmuth is a scholar working on Hematology, Molecular Biology, Pathology and Forensic Medicine, Cancer Research and Computational Theory and Mathematics, having authored 69 papers that have together received 15.2k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (18 papers), RNA Research and Splicing (9 papers), Protein Kinase Regulation and GTPase Signaling (8 papers), Hedgehog Signaling Pathway Studies (7 papers), Computational Drug Discovery Methods (6 papers), Lung Cancer Treatments and Mutations (5 papers), Cancer Genomics and Diagnostics (5 papers) and Cancer Mechanisms and Therapy (4 papers). The work is most often cited by research in Hematology (2k citations), Cancer Research (1.8k citations), Molecular Biology (6.4k citations), Computational Theory and Mathematics (1.6k citations) and Oncology (2.1k citations). Markus Warmuth has collaborated with scholars based in United States, Germany and Switzerland. Frequent co-authors include Michael J. Hallek, Doriano Fabbro, Katja Zirlik, Christine Dierks, Hendrik Veelken, Gang Xia, Susanne Danhauser-riedl, Paul William Manley, Francisco Adrián and Marion Dorsch. Their work appears in journals such as Blood, Nature, Cancer Research, Nature Medicine and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.